IRIS
LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.898
AS - Asia 3.452
NA - Nord America 2.715
Continente sconosciuto - Info sul continente non disponibili 437
SA - Sud America 280
AF - Africa 59
OC - Oceania 6
Totale 35.847
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.243
US - Stati Uniti d'America 2.528
SG - Singapore 1.399
CN - Cina 866
VN - Vietnam 483
BD - Bangladesh 403
FR - Francia 276
BR - Brasile 166
FI - Finlandia 140
HK - Hong Kong 103
CA - Canada 68
DE - Germania 64
AR - Argentina 46
MX - Messico 40
JP - Giappone 39
GB - Regno Unito 32
IN - India 27
CH - Svizzera 24
IQ - Iraq 24
EC - Ecuador 15
JM - Giamaica 14
PH - Filippine 14
ID - Indonesia 13
NL - Olanda 13
CO - Colombia 12
CR - Costa Rica 12
KR - Corea 12
UA - Ucraina 12
CL - Cile 11
MA - Marocco 11
PY - Paraguay 11
RU - Federazione Russa 11
VE - Venezuela 10
ES - Italia 9
HN - Honduras 9
KE - Kenya 9
TR - Turchia 9
IE - Irlanda 8
UZ - Uzbekistan 8
BB - Barbados 7
MY - Malesia 7
TT - Trinidad e Tobago 7
AU - Australia 6
EG - Egitto 6
RO - Romania 6
TH - Thailandia 6
TN - Tunisia 6
ZA - Sudafrica 6
AL - Albania 5
GT - Guatemala 5
NI - Nicaragua 5
NP - Nepal 5
PK - Pakistan 5
PT - Portogallo 5
SE - Svezia 5
SV - El Salvador 5
GR - Grecia 4
HU - Ungheria 4
SA - Arabia Saudita 4
SI - Slovenia 4
UY - Uruguay 4
AT - Austria 3
AZ - Azerbaigian 3
BE - Belgio 3
BG - Bulgaria 3
BO - Bolivia 3
BS - Bahamas 3
DO - Repubblica Dominicana 3
GD - Grenada 3
LT - Lituania 3
MD - Moldavia 3
PL - Polonia 3
PR - Porto Rico 3
RS - Serbia 3
SC - Seychelles 3
AO - Angola 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
HR - Croazia 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
PE - Perù 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
CG - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
GE - Georgia 1
GH - Ghana 1
GN - Guinea 1
HT - Haiti 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
Totale 35.392
Salva come PNG Salva come JPEG
Città #
Genova 16.750
Genoa 6.914
Rapallo 2.489
Vado Ligure 1.685
Singapore 652
San Jose 487
Lauterbourg 245
Ashburn 241
Ho Chi Minh City 150
Helsinki 131
New York 127
Beijing 108
Hanoi 107
Council Bluffs 99
Hong Kong 96
Santa Clara 70
Los Angeles 69
Bordighera 61
Frankfurt am Main 54
Rome 38
Boardman 32
Milan 32
Bar Harbor 31
Tokyo 31
Dallas 28
Tianjin 27
Chicago 26
Haiphong 25
Buffalo 23
Mexico City 21
Phoenix 21
St Louis 20
São Paulo 20
Zurich 19
Naples 18
Da Nang 17
Orem 16
Piscataway 16
Atlanta 15
Houston 14
Toronto 14
Brooklyn 13
Columbus 13
Miami 13
Paris 13
Philadelphia 13
Detroit 12
Baghdad 11
Hải Dương 11
Portland 11
San José 11
Shanghai 11
Washington 11
Charlotte 10
Denver 10
Las Vegas 10
Turin 10
Amsterdam 9
Bologna 9
Kingston 9
Lappeenranta 9
Montreal 9
Newark 9
Palermo 9
Queens 9
Dublin 8
Guangzhou 8
Nairobi 8
Ninh Bình 8
Boston 7
City of London 7
Florence 7
Fredericksburg 7
Greenville 7
Istanbul 7
London 7
Madrid 7
Parma 7
San Francisco 7
Schiavon 7
Tampa 7
Biên Hòa 6
Bridgetown 6
Cincinnati 6
Des Moines 6
Garland 6
Hangzhou 6
Janesville 6
Lakeland 6
North Bergen 6
Nuremberg 6
Tashkent 6
Alexandria 5
Baltimore 5
Bari 5
Cairo 5
Cardiff 5
Chennai 5
Cleveland 5
Clifton 5
Totale 31.516
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 250
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 228
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 227
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 220
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 215
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 211
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 204
T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. 202
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 200
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 200
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 198
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 188
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 184
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 180
Harnessing NK Cells for Cancer Treatment 178
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 177
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study 177
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 176
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 176
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 175
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 175
T lymphocyte killing by a xanthine-oxidase-containing immunotoxin. 174
C-kit ligand (SCF) in human multiple myeloma cells. 171
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 170
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 170
Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma 170
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 170
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia 167
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 166
Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series 166
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. 165
Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. 164
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 164
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 164
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 164
A novel model of CCl4-induced cirrhosis with ascites in the mouse. 163
Viability of autologous bone marrow. 162
CD103 Marks a Subset Of Human CD34+-Derived Langerin+ Dendritic Cells Which Induce T Regulatory Cells Via Indoleamine 2,3-Dioxygenase-1. 162
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 161
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 159
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. 159
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 158
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. 158
Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects. 156
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 156
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 156
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 155
The CD47 pathway is deregulated in human immune thrombocytopenia. 155
Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients. 155
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 155
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes 155
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 153
Autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma: comparison of different parameters in predicting the kinetics of haematological recovery. 151
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 150
The P2X7 receptor: a key player in IL-1 processing and release. 149
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia 149
Autologous bone marrow transplantation with marrow cryopreserved for ten years. 148
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program 148
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 148
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 148
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 146
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: A GITMO survey on 809 patients autografted in first complete remission 146
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 146
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. 145
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. 145
Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. 145
Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. 144
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. 144
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 143
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. 142
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. 141
Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). 141
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 141
Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. 141
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. 141
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. 141
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. 141
Interleukin-11 induces Th2 polarization of human CD4(+) T cells. 140
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. 140
Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 140
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 139
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 139
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. 139
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial 139
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors 138
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 138
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets. 138
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. 138
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 138
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 138
Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. 137
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. 137
Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. 137
Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying hematological recovery. 137
Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. 137
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 137
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. 136
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 136
Purging in autologous and allogeneic bone marrow transplantation. 136
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 135
Totale 15.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.110
article - articoli 108.865
book - libri 0
conference - conferenze 770
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.475
Totale 224.220
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.954 57 121 67 360 234 231 233 647 111 287 80 526
2022/20233.127 357 279 68 357 474 525 5 266 486 31 224 55
2023/20241.464 66 180 71 165 109 277 99 142 77 29 78 171
2024/20254.282 62 368 169 301 529 418 455 566 145 255 428 586
2025/20268.895 864 348 661 763 978 869 1.348 392 642 790 646 594
2026/20271.032 1.032 0 0 0 0 0 0 0 0 0 0 0
Totale 35.847